Gene: DGKI

9162
DGK-IOTA
diacylglycerol kinase iota
protein-coding
7q33
Ensembl:ENSG00000157680 MIM:604072 Vega:OTTHUMG00000155697 UniprotKB:O75912
NC_000007.14
SNP Mapped
ND
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
4.604e-1 (AD)  3.095e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs7804771chr7:137447847 (GRCh38.p7)C>Gnicotine dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
NBEA0.961
RYR20.955
MYCBP20.953
SLC8A10.952
FRMPD40.951
ZC3H12B0.951
SAMD120.95
ADAM220.95
ATL10.95
FAXC0.948

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
RAB13-0.595
COPZ2-0.577
MYL3-0.57
HEY2-0.554
RNF135-0.552
CSAG1-0.55
EMP3-0.542
ROM1-0.541
CHST14-0.539
FLT3LG-0.538

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DGKI mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DGKI mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DGKI mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DGKI mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DGKI mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DGKI mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DGKI mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DGKI mRNA"27188386
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of DGKI gene27153756
D000643Ammonium ChlorideAmmonium Chloride affects the expression of DGKI mRNA16483693
D018501Antirheumatic AgentsAntirheumatic Agents results in increased expression of DGKI mRNA24449571
C006632arsenic trioxidearsenic trioxide results in increased expression of DGKI mRNA20458559
C015001arsenitearsenite affects the expression of DGKI mRNA22959463
C547126AZM551248AZM551248 results in increased expression of DGKI mRNA22323515
C487081belinostat"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DGKI mRNA"27188386
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of DGKI mRNA22316170
C006780bisphenol Abisphenol A results in decreased expression of DGKI mRNA25181051
C006780bisphenol Abisphenol A results in increased expression of DGKI mRNA29097150
C006780bisphenol Abisphenol A results in increased methylation of DGKI gene28505145
D020245p-Chloromercuribenzoic Acid"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DGKI mRNA"27188386
D020245p-Chloromercuribenzoic Acidp-Chloromercuribenzoic Acid results in decreased expression of DGKI mRNA26272509
D003300CopperCopper deficiency results in increased expression of DGKI mRNA26033743
D003471CuprizoneCuprizone results in decreased expression of DGKI mRNA26577399
D004026DieldrinDieldrin results in increased expression of DGKI mRNA28385952
D004041Dietary FatsDietary Fats results in increased expression of DGKI mRNA25016146
D019422Dietary SucroseDietary Sucrose results in increased expression of DGKI mRNA26033743
D004052Diethylnitrosamine[Diethylnitrosamine co-treated with Phenobarbital] results in decreased methylation of DGKI promoter25374375
D004052Diethylnitrosamine[Diethylnitrosamine co-treated with Phenobarbital] results in increased expression of DGKI mRNA25374375
D004317DoxorubicinDoxorubicin results in decreased expression of DGKI mRNA16404146
D004997Ethinyl EstradiolEthinyl Estradiol results in increased expression of DGKI mRNA29097150
D008344Maneb[Paraquat co-treated with Maneb] affects the expression of DGKI mRNA22563483
C042720mercuric bromidemercuric bromide results in decreased expression of DGKI mRNA26272509
C042720mercuric bromide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DGKI mRNA"27188386
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of DGKI mRNA23103053
C029938nickel sulfatenickel sulfate results in decreased expression of DGKI mRNA22714537
D010269Paraquat[Paraquat co-treated with Maneb] affects the expression of DGKI mRNA22563483
D010269ParaquatParaquat results in increased expression of DGKI mRNA22563483
C086401pentabromodiphenyl etherpentabromodiphenyl ether results in decreased expression of DGKI mRNA26705709
D010634Phenobarbital[Diethylnitrosamine co-treated with Phenobarbital] results in decreased methylation of DGKI promoter25374375
D010634Phenobarbital[Diethylnitrosamine co-treated with Phenobarbital] results in increased expression of DGKI mRNA25374375
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DGKI mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in decreased expression of DGKI mRNA26272509
C027373potassium chromate(VI)potassium chromate(VI) results in decreased expression of DGKI mRNA22714537
D011374ProgesteroneProgesterone results in decreased expression of DGKI mRNA19690047
D011441PropylthiouracilPropylthiouracil results in decreased expression of DGKI mRNA24780913
C428725pyridabenpyridaben results in increased expression of DGKI mRNA22563483
C017947sodium arsenitesodium arsenite results in decreased expression of DGKI mRNA22714537
D014212TretinoinTretinoin results in decreased expression of DGKI mRNA21934132
D014212TretinoinTretinoin results in increased expression of DGKI mRNA23724009
C012589trichostatin Atrichostatin A results in decreased expression of DGKI mRNA24935251
C012589trichostatin Atrichostatin A results in increased expression of DGKI mRNA24935251
D014635Valproic AcidValproic Acid affects the expression of DGKI mRNA25979313
D014635Valproic AcidValproic Acid results in increased expression of DGKI mRNA24935251|2800136
D014639VanadiumVanadium results in increased expression of DGKI mRNA19000753

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0003951NAD+ kinase activity-IEA-  
GO:0004143diacylglycerol kinase activity-IDA9830018  
GO:0004143diacylglycerol kinase activity-TAS-  
GO:0005095GTPase inhibitor activity-IEA-  
GO:0005515protein binding-IPI17986458  
GO:0005524ATP binding-IEA-  
GO:0017016Ras GTPase binding-IEA-  
GO:0046872metal ion binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0007205protein kinase C-activating G-protein coupled receptor signaling pathway-IEA-  
GO:0007269neurotransmitter secretion-IEA-  
GO:0030168platelet activation-TAS-  
GO:0034260negative regulation of GTPase activity-IEA-  
GO:0035556intracellular signal transduction-IEA-  
GO:0046579positive regulation of Ras protein signal transduction-IEA-  
GO:0046834lipid phosphorylation-IDA9830018  
GO:0046959habituation-IEA-  
GO:0051966regulation of synaptic transmission, glutamatergic-IEA-  
GO:0060079excitatory postsynaptic potential-IEA-  
GO:1900452regulation of long term synaptic depression-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005634nucleus-IDA9830018  
GO:0005654nucleoplasm-IDA-  
GO:0005737cytoplasm-IDA9830018  
GO:0005829cytosol-IEA-  
GO:0005886plasma membrane-TAS-  
GO:0008021synaptic vesicle-IEA-  
GO:0014069postsynaptic density-IEA-  
GO:0032045guanyl-nucleotide exchange factor complex-IEA-  
GO:0032991protein-containing complex-IDA21119615  
GO:0043025neuronal cell body-IEA-  
GO:0043197dendritic spine-IDA21119615  
GO:0043679axon terminus-IEA-  
GO:0045202synapse-IDA21119615  
GO:0048471perinuclear region of cytoplasm-IEA-  
GO:0048786presynaptic active zone-IEA-  
GO:0060076excitatory synapse-IEA-  
GO:0097060synaptic membrane-IEA-  
KEGG ID KEGG Term
hsa00561Glycerolipid metabolism
hsa00564Glycerophospholipid metabolism
hsa01100Metabolic pathways
hsa04070Phosphatidylinositol signaling system
Reactome ID Reactome Term Evidence
R-HSA-109582HemostasisTAS
R-HSA-114508Effects of PIP2 hydrolysisTAS
R-HSA-162582Signal TransductionTAS
R-HSA-372790Signaling by GPCRTAS
R-HSA-388396GPCR downstream signallingTAS
R-HSA-416476G alpha (q) signalling eventsTAS
R-HSA-76002Platelet activation, signaling and aggregationTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal